Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Wants To Reduce Amevive Copay, Adds Pharmacy Distribution

Executive Summary

Biogen is pursuing initiatives to reduce the copay burden for patients taking the psoriasis agent Amevive

You may also be interested in...



Biogen Closing Gap On Amevive Reimbursement: Pre-Authorization At 30%

The percentage of Amevive patients needing prior authorization for the psoriasis biologic has shrunk to 30%, Biogen Idec CEO Jim Mullen told investors Jan. 12 at the J.P. Morgan health care cconference in San Francisco

Biogen Closing Gap On Amevive Reimbursement: Pre-Authorization At 30%

The percentage of Amevive patients needing prior authorization for the psoriasis biologic has shrunk to 30%, Biogen Idec CEO Jim Mullen told investors Jan. 12 at the J.P. Morgan health care cconference in San Francisco

Genentech/Xoma Raptiva Clears FDA, Priced At 25% Discount to Amevive

Genentech/Xoma's psoriasis therapy Raptiva will be available by Thanksgiving at a 25% discount to a full year of Biogen's intramuscular injection formulation of Amevive

Related Content

UsernamePublicRestriction

Register

PS042726

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel